loading page

Epitope Screening Using Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS): An Optimized Workflow for Accelerated Evaluation of Lead Monoclonal Antibodies
  • +3
  • Shaolong Zhu,
  • Peter Liuni,
  • Tricia Chen,
  • Camille Houy,
  • Derek Wilson,
  • Andrew James
Shaolong Zhu
Sanofi Pasteur Ltd

Corresponding Author:[email protected]

Author Profile
Peter Liuni
York University
Author Profile
Tricia Chen
Sanofi Pasteur Ltd
Author Profile
Camille Houy
Sanofi Pasteur Ltd
Author Profile
Derek Wilson
York University
Author Profile
Andrew James
Sanofi Pasteur Ltd
Author Profile

Abstract

Background: Epitope mapping is an increasingly important aspect of biotherapeutic and vaccine development. Recent advances in therapeutic antibody design and production has enabled candidate mAbs to be identified at a rapidly increasing rate resulting in a significant bottleneck in the characterization of ‘structural’ epitopes, that are challenging to determine using existing high throughput epitope mapping tools. Here, Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS) epitope screening workflow was introduced that is well suited for accelerated characterization of epitopes with a common antigen. Main methods and major results: The method is demonstrated on set of 6 candidate mAbs targeting Pertactin (PRN). Using this approach, five of the six epitopes was unambiguously determined using two HDX mixing timepoints in 24 hours total run time, corresponding to substantial decrease in the instrument time required to map a single epitope using conventional HDX workflows. Conclusion: An accelerated HDX-MS epitope screening workflow was developed. The two-timepoint ‘screening’ workflow mapped all six mAbs and generated high confidence epitopes for five of the six mAbs assayed. The substantial improvement in the rate of data collection can advance HDX-MS for higher throughput investigations supporting the ability to evaluate a broader number of mAb candidates at an earlier stage of vaccine development.
09 Jul 2021Submitted to Biotechnology Journal
10 Jul 2021Submission Checks Completed
10 Jul 2021Assigned to Editor
27 Jul 2021Reviewer(s) Assigned
18 Aug 2021Editorial Decision: Revise Major
18 Oct 20211st Revision Received
19 Oct 2021Assigned to Editor
19 Oct 2021Submission Checks Completed
19 Oct 2021Reviewer(s) Assigned
01 Nov 2021Editorial Decision: Revise Minor
02 Nov 20212nd Revision Received
03 Nov 2021Submission Checks Completed
03 Nov 2021Assigned to Editor
03 Nov 2021Reviewer(s) Assigned
03 Nov 2021Editorial Decision: Accept
Feb 2022Published in Biotechnology Journal volume 17 issue 2 on pages 2100358. 10.1002/biot.202100358